OXFORD, Miss. (PRWEB) October 26, 2018
Oxford Urology Associates today announced that Dr. Brent Hardin has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Hardin has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH.
“The UroLift System has fundamentally changed how I treat men in my practice who have symptoms associated with BPH,” said Dr. Hardin. “Patients are experiencing rapid symptom relief and are often able to discontinue the use of ongoing BPH medications. It won’t be long before the UroLift System becomes the standard of care for treating BPH patients.”
Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.
Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.
Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.
About the UroLift System
NeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea.
Learn more at http://www.UroLift.com.
What Is the UroLift® System?
Treatment with the UroLift® System is typically a one-time, 15 minute solution that provides rapid relief and recovery for men living with symptoms of an enlarged prostate. It breaks the cycle of medications and how they make a person feel, all without the risks of traditional surgery. The goal of the UroLift System treatment is to relieve symptoms so you can get back to your life and resume your daily activities.
Most men living with enlarged prostate (BPH) symptoms take prescription medications after they’re diagnosed but these prescriptions often don’t provide adequate relief and may cause dizziness, fatigue, and sexual dysfunction. Medications don’t need to become a lifelong burden and men don’t need to wait until surgery is required to address the problem. With the UroLift System treatment, men suffering from BPH symptoms can avoid traditional surgery altogether.
There’s a better option that can help men feel revitalized without having to compromise: The UroLift System treatment. This is typically a one-time, in-office procedure that is a straightforward solution to treat the blockage, freeing men from ongoing BPH medications with a rapid recovery.
Before Implant- Prostate Obstructs Bladder Outflow
Post Urolift- No Longer Obstructed
A Minimally Invasive BPH Treatment
The simple UroLift System treatment typically performed in less than 15 minutes that uses tiny implants to hold open the obstructed pathway that’s blocking urine flow, addressing the blockage, not just continuously treating enlarged prostate (BPH) symptoms. Most patients return home immediately and experience a speedy recovery. A catheter might be needed for less than 24 hours.
Why the UroLift System?
The UroLift System provides a proven treatment that can get men off BPH medications which can make a person feel foggy and cause sexual dysfunction.1,2 Treatment with the UroLift System has a risk profile better than surgical procedures that may have serious complications and a long, painful recovery.2-5 The treatment may be right for you if any of the following apply:
-You want a BPH solution that preserves your sexual function*
-You do not want to take a pill for BPH
-You tried BPH medication and are unhappy with the side effects
-You do not want to undergo major surgery due to risks of complications and side effects
-You want to regain your quality of life with limited downtime
-You want a minimally invasive treatment
1. Roehrborn et al. Can J Urol 2017
2. AUA Guidelines 2003
3. Wasson, Perspectives in Nursing 2000
4. NIH U.S. National Library of Medicine – TURP patient instructions https://medlineplus.gov/ency/patientinstructions/000300.htm
5. Sonksen, EU Urol, 2015 BPH6 Study